Arvinas Set to Attend Upcoming Investor Conferences
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 28 2025
0mins
Source: Globenewswire
Arvinas, Inc. Investor Conferences
- Upcoming Conferences: Arvinas, Inc. will participate in fireside chats at the Wells Fargo Healthcare Conference on September 4 and the Cantor Global Healthcare Conference on September 5. Live audio webcasts of these presentations will be accessible on the company's website.
About Arvinas
- Company Overview: Arvinas is a clinical-stage biotechnology firm focused on developing targeted protein degradation therapies to treat serious diseases. The company utilizes its proprietary PROTAC platform to create drugs that can selectively degrade harmful proteins in the body.
- Investigational Drugs: Arvinas is advancing several investigational drugs through clinical trials, including:
- Vepdegestrant: Targets the estrogen receptor for patients with advanced ER+/HER2- breast cancer.
- ARV-393: Aims at BCL6 for treating relapsed/refractory non-Hodgkin Lymphoma.
- ARV-102: Focuses on LRRK2 for neurodegenerative disorders.
- ARV-806: Targets KRAS G12D mutations in cancers such as pancreatic and colorectal cancers.
- Headquarters: The company is based in New Haven, Connecticut, and provides further information through its website and social media platforms.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
